On February 28, 2020, a Rhode Island man filed a lawsuit in the U.S. District Court of Rhode Island against Zantac. The lawsuit alleges that he developed bladder cancer as a result of taking the heartburn drug five (5) times a week for six (6) years. This product liability lawsuit joins the growing number of lawsuits being filed against the drug manufacturers after cancer risks have emerged. This case will likely join others in the U.S. District Court for the Southern District of Florida, where this MDL (Multidistrict Litigation) is being centralized.
What Makes Zantac Potentially Dangerous?
Since October 2019, after the FDA announced its finding on Zantac, the drug has been recalled for its link to causing digestive cancer. The main culprit is the drugs active ingredient, ranitidine. When mixed with water, ranitidine produces a substance called N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen. NDMA is widely known to be hazardous, especially to a person’s bladder, liver and stomach.
The crux of the issues stemming from these lawsuits is that the manufacturers of Zantac were allegedly well aware of these risks and did not warn anybody. There was research in the past that showed this very clear link between ranitidine and NDMA. Yet despite the research shown, manufacturers chose not to disclose this information to the public or the government. Now, many others have filed similar suits stating their cancer was a result of taking Zantac. Along with bladder cancer, others have claimed to have developed colorectal, esophageal, kidney, liver and stomach cancer.
Contact an Experienced Zantac Lawyer Today!
If you or a loved one took Zantac and was later diagnosed with a form of digestive cancer, you may be entitled to compensation for your medical costs, lost wages, pain and suffering and other related losses. We work with experienced Zantac Lawyers around the nation who charge no fees unless you receive a settlement or award. Call us toll-free at 800-992-6878 or fill out a contact form online for a free (no obligation) case evaluation.